Continuous Glucose Monitoring– tag –
-
Wearable Device ‘Disappearing Act’ Accelerates as Dexcom’s Latest CGM Shrinks by 50%
ZDNET USA Overview Wearable devices are evolving towards 'invisible' designs to integrate more naturally into users' lifestyles, aiming to minimize their presence and enable more consistent wear, thereby enhancing user experience. Dexcom... -
Precision and Provenance: Why Regulatory Approval and MARD Transparency Define the Future of Glucose Monitoring
Mattioli 1885 イタリア Overview A recent report on the 2026 glucose monitoring market highlights the transformative role of Continuous Glucose Monitoring (CGM) in diabetes management. It underscores that robust quality indicators—specifi... -
2026 Digital Blood Sugar Meters: CGM Revolutionizes Metabolic Awareness with Real-Time Trends and Historical Data
[Unnamed Health Publication] Unknown Overview An analysis of digital blood sugar meters in 2026 highlights the distinction between traditional meters, which provide single readings, and Continuous Glucose Monitoring (CGM) devices that of... -
Abbott’s FreeStyle Libre Offers 10-Day Real-Time Glucose Monitoring for Diabetes Patients Aged 4 and Up
Health Insider Canada Overview Abbott Laboratories' FreeStyle Libre system provides continuous glucose monitoring for diabetes patients aged four and older, utilizing a small wearable sensor and a smartphone app. This system delivers rea... -
FDA Warns: Smartwatches Lack Medical-Grade Accuracy for Non-Invasive Blood Glucose Monitoring in 2026
[Unnamed Health Publication] USA Overview As of 2026, peer-reviewed research on non-invasive blood glucose monitoring via consumer wearables remains limited. The FDA and Johns Hopkins University explicitly state no wrist-worn device exis... -
Non-Invasive Blood Sugar Monitoring Faces Accuracy and Reliability Hurdles; True Non-Invasive Devices Remain Undeveloped
Health.com USA Overview While non-invasive blood sugar meters hold promise for finger-prick-free glucose checks, most currently available devices fail to meet the expected medical-grade accuracy and reliability for daily tracking. Many p... -
Dorsey & Whitney Trust CO LLC Sells Abbott Laboratories Shares Amidst Focus on Libre Duo CE Mark Approval
MarketBeat USA Overview Dorsey & Whitney Trust CO LLC has reduced its holdings in Abbott Laboratories shares. Despite this divestment, Abbott is gaining significant attention for its recent CE Mark approval of Libre Duo, an innovativ... -
Erste Group Bank Adjusts Abbott’s FY2027 Earnings Outlook Downward, Highlights Libre Duo CE Mark as Key Growth Driver
MarketBeat USA Overview Erste Group Bank has slightly lowered its fiscal year 2027 earnings outlook for Abbott Laboratories, yet emphasizes Abbott's recent CE Mark approval for its innovative Libre Duo dual glucose-ketone sensing technol... -
Diabetes Devices Dominate FDA MAUDE Reports 2020-2025 with Over 50% of Adverse Events, Dexcom Largest Single Reporter
Global MedTech Expert | 10× MedTech Global Access Unknown Overview An analysis of 14.4 million FDA MAUDE adverse event reports from 2020 to 2025 reveals that diabetes-related devices account for over half of all reported events. Continuo... -
Supply Chain Integrity Under Fire: Pharmsource Denies Knowledge of Stolen, Recalled Dexcom G7 Sensors
Investing.com 南アフリカ Overview Pharmaceutical wholesaler Pharmsource LLC denies knowing that Dexcom G7 continuous glucose monitoring (CGM) sensors it acquired were stolen post-disposal and resold, despite being originally slated for d...
